Michael Muenzberg

Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians

Hillel P. Cohen, Donna Beydoun, David Chien et al. · Advances in Therapy · 2016 · 208 citations · Full text

Medicine, Clinical Sciences, Medical Education +13

Development of a new G-CSF product based on biosimilarity assessment

Pere Gascón, Uwe Fuhr, F. Sörgel et al. · Annals of Oncology · 2009 · 90 citations · Full text

Pharmacy, Biotechnology, Biopharmaceutics +7

Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim

Pere Gascón, Matti Aapro, Heinz Ludwig et al. · Critical Reviews in Oncology/Hematology · 2010 · 24 citations

Medicine, Pharmacology, Pharmacotherapy +14

Bioequivalence Studies of Omnitrope, the First Biosimilar/rhGH Follow‐on Protein: Two Comparative Phase 1 Randomized Studies and Population Pharmacokinetic Analysis

R Stanhope, Fritz Sörgel, Patricia Gravel et al. · The Journal of Clinical Pharmacology · 2010 · 23 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +14

Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: Initial evidence from the RESPOND study

Matti Aapro, Joanna Van Erps, Karen MacDonald et al. · European Journal of Cancer · 2008 · 23 citations

Medicine, Hematology, Oncology +10